(Axios) – The apps could boost the drugs’ clinical value and provide a more personalized approach to managing chronic conditions such as depression, obesity and musculoskeletal problems. But the combinations are blurring the line between digital health and medicines and putting the Food and Drug Administration on the hook for making sure the software works and doesn’t pose an increased risk to patient safety. (Read More)